Connect with us

Featured

Premier Health (OTC:PHGRF) (CSE:PHGI) Signs Definitive Agreement for Acquisition of Cloud Practice Inc., a National Medical Software Application Company

Joe Samuel

Published

on

  • Cloud Practice Inc. products include: Juno EMR, a cloud based EMR solution; ClinicAid, a medical billing software; and MyHealthAccess, an online patient portal
  • The Juno EMR system is currently used by 287 clinics, over 3,000 licensed practitioners, 1,500 staff and 2,870,000 registered patients
  • Cloud Practice services over 60 Cannabis Clinics with over 120,000 active patients.
  • ClinicAid processes upwards of $30,000,000 in payments to over 3000 health providers on a monthly basis

VANCOUVER, British Columbia, January 10, 2018 – Premier Health Group Inc. (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry, is pleased to announce, further to its news release dated December 17, 2018, the Company has signed a Definitive Agreement (“the Agreement”) to acquire all of the outstanding securities of Cloud Practice Inc. (“Cloud Practice”).

EXCLUSIVE: Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

Cloud Practice’s founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers. The combined Premier and Cloud Practice ecosystem consists of over 3,000,000 patients.

“We are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system,” said Dr. Essam Hamza, CEO of Premier.

Jordan Visco, CEO of Cloud Practice, stated: “We are thrilled to be joining a progressive group such as Premier Health. We are focused on delivering top quality service to Canada’s healthcare industry and we are confident that with Cloud Practice’s offerings combined with the Premier Health teams’ expertise and long-term vision, we can achieve considerable success.”

In consideration for the acquisition of all of the outstanding Cloud Practice securities, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and (v) an aggregate of $3 million payable in common shares of Premier at a deemed price of $0.76 per share.

All shares issued in the transaction are subject to a restricted period of four months and one day. There were no finder’s fees paid in connection with the Transaction.

ON BEHALF OF THE BOARD OF DIRECTORS

“Dr. Essam Hamza, MD”

Chief Executive Officer

 

About Premier Health

 

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are developing innovative health care approaches that combine human skill based expertise with emerging technologies, with the goal of setting the gold standard for services in locations of interest worldwide. Premier Health’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The HealthVue team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.

 

About Cloud Practice

 

Cloud Practice is a cloud-based software solutions company focused on streamlining medical practice throughout Canada. They offer three products including Juno EMR, ClinicAid and MyHealthAccess. Juno EMR, a modified branch of an open-source electronic medical records (EMR) software which was originally released by McMaster University, is hosted in the cloud and can be accessed anywhere, anytime. ClinicAid is Canada’s easiest medical billing software. MyHealthAccess is an online patient portal which puts patients back in control of their health care through connecting with their clinics and booking appointments online.

Cautionary Statements

This news release contains forward-looking statements that are based on Premier Health’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans, completion of its acquisition of Cloud Practice, and the timing thereof, the expected benefits to the Company following the integration of Cloud Practice’s software and the expected implementation of new applications, including the timing thereof, the expect growth to Cloud Practice’s business and the expected synergies resulting from the Company’s acquisition of Cloud Practice. Although Premier Health believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Premier Health undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

FOR ADDITIONAL INFORMATION CONTACT:

Premier Health Group Inc.

www.mypremierhealth.com

Email: investors@mypremierhealth.com

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full disclaimer.

Continue Reading
Click to comment

Featured

Biotechnology Could Cure It All

Daniel Chase

Published

on

stock_price_biotech

Nearly two-thousand years ago, give or take several minutes, Hippocrates taught that human existence was centered around the four elements — earth, water, fire, and air — which in the human body was represented by the four basic humors: blood, phlegm, black bile, yellow bile. Hippocrates explained that each humor was located in a specific organ of the human body and each related to its own personality type — sanguine, phlegmatic, melancholic, and choleric.

‘Therefore, if someone was sick, Hippocrates taught that this indicated an imbalance in one of the four humors, so treatment included removing a given amount of the imbalanced humor through purging, bloodletting, etc. For those unfamiliar with bloodletting, it is the removal of some a patient’s blood which, in modern times, seems completely feasible, but back then this involved draining blood out of a person. 

Suffice to say that the medical field has moved forward since 460 BC, and recently, these advancements have occurred in the biotechnology industry. Though biotech is a relatively new field, it possesses great potential for the future of medicine. One of the more recent breakthroughs in biotech stems from something called pharmacogenomics, or the study of how genetics affect a person’s response to drugs. This new field combines the science of developing drug treatments and research conducted on human genetics and their functions. 

Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

According to the U.S. National Library of Medicine, most drugs currently available on the market are branded as “one size fits all,”meaning that this specific treatment was created to cure a certain ailment for anyone who takes it. However, as scientists in the pharmacogenomics field are discovering, not everyone reacts the same to certain drugs.

For example, if two individuals are having an allergic reaction and both ingest an anti-histamine, it’s possible that it will help one person feel better, while causing adverse side-effects to the other person. By studying a person’s genetic coding, medical experts are better able to predict how a medication will effect a particular person. 

Ironically enough, as new technologies and inventive approaches to curing diseases come to light, medical researchers are discovering new diseases that seek to test all the progress we’ve made thus far. The practices of medicine have taken massive strides over the past few generations through the pioneering of biotechnology research and other incredible advancements, but regardless of these steps forward, it is up to companies in the healthcare industry to responsibly tend to the needs of their patients. 

Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F) is a Canadian publicly traded company strategically poised to take advantage of lucrative business opportunities in the global healthcare industry. The Company is working to develop innovative healthcare approaches that combine human skill-based expertise with emerging technologies. What sets the Company apart from others in the field is that Premier is focused on developing their healthcare platform with a patient centric focus, looking to restore power back to the patients. For far too long, patients have been at the mercy of pharmaceutical companies who, by virtue of their capital, have maintained a chokehold on the price of drugs that patients need to stay healthy. 

In addition to rising treatments costs, as the global population increases, there are less primary physicians available for consumers looking to be cured. Through the use of Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) / (6PH.F) HealthVue app, patient can see their physician, access their charts & lab results, chat securely with clinical staff, reorder prescriptions and share remote health monitoring data with their doctor – all at their fingertips. The HealthVue app utilizes a virtual care platform designed to be easy to use and to improve a patient’s access to primary care. 

In addition these advanced healthcare solutions, the Company shared, in their most recent corporate update, that they plan on utilizing artificial intelligence to assist in virtually triaging the needs of their patients. Using their Healthvue app, the patient will answer a series of questions which will be relayed to the physician, along with a differential on possible diagnoses. This information will be pre-populated to the physicians charting system and will provide key patient information prior to the scheduled virtual visit, saving them a considerable amount of time and allowing more time for patient interaction. 

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Continue Reading

Featured

Stock Price Newsletter – February 21, 2019

Joe Samuel

Published

on

stock price newsletter

One Stock To Watch Ahead Of Healthcare Boom

See For Yourself


The Future Is Delicious

Details Here


Here’s What You Missed 2/20/19

Get The Full Story Here


Continue Reading

Featured

Mueller Investigation Is Almost Ready

Daniel Chase

Published

on

stock_price_mueller

A half-witted, know-nothing playwright by the name of William Shakespeare once wrote that “these violent delights have violent ends.” The line, taken from Shakespeare’s Romeo and Juliet, also featured in Westworld, depicts a scene in which Friar Laurence cautions Romeo into falling for Juliet because his love may catalyze his own violent end. I attribute the words of Shakespeare to the current predicament facing President Donald Trump and his administration. In the two or so years since Trump took office, special counsel Robert Mueller has worked without end to investigate whether the Trump administration colluded in any way, shape, or form, with Russia during the 2016 presidential election. 

After countless subpoenas and inducements of former Trump associates and administration members, sources indicate that Mueller’s long nights away from the family could soon be over. Towards that end of January, Roger Stone, a former associate of Donald Trump before he became president, was indicted on charges of seeking stolen emails from WikiLeaks that could damage Trump’s opponents during the 2016 presidential election season. 

Per the official language of the indictment:

“…After the 2016 U.S. presidential election, the U.S. House of Representatives Permanent Select Committee on Intelligence, the U.S. Senate Select Committee on Intelligence, and the Federal Bureau of Investigation opened or announced their respective investigations into Russian interference in the 20126 U.S. presidential election…Stone took steps to obstruct these investigations….He made false statements to the HPSCI about his interactions regarding WikiLeaks, and falsely denied possessing records that contained evidence…”

-Robert Stone indictment 

The indictment went on to explain that Stone attempted to persuade a witness to provide false testimony and withheld pertinent information from federal investigators. According to several sources, Stone was arrested by the FBI Friday morning while drinking his morning coffee at his home in Florida. Stone’s attorney immediately attempted to defuse any public sentiment stirring up connecting Stone to special counsel Mueller’s investigation, suggesting that Stone’s indictment “focuses on allegedly false statements…made to Congress,” and has nothing to do with Russian collusion. 

According to CNN, Attorney General Bill Barr is limbering up in preparation to announce as early as next week the completion of Robert Mueller’s investigation, “with plans for Barr to submit to Congress soon after a summary” of the confidential report is prepared. Interestingly enough, though the details of the report concern both the American people and its presiding government, under special counsel regulations, Mueller must submit his “report” to the attorney general and the law doesn’t require this document to be shared with anyone.

Barr is under no formal obligation to publicly share the report, but I can already assume that members of the Democratic leadership will be banging on his office door until he throws them a bone. 

The question on everyone’s mind is, what Mueller discovered in his lengthy investigation. Mueller was appointed to the case on May 17, 2017, and in years following this date, Mueller has had his hands full. Early last week, Mueller’s office filed its sentencing memorandum against Paul Manafort, Trump’s former campaign manager, who will be sentenced next month in federal district court in the District of Columbia. 

“For a decade, Manafort repeatedly violated the law. Considering only the crimes charged in this district, they make plain that Manafort chose to engage in a sophisticated scheme to hide millions of dollars from United States authorities. The sentence in this case must take into account the gravity of this conduct, and serve to both specifically deter Manafort and those who would commit a similar series of crimes.”

sentencing memo from Robert Mueller

As for the findings of Mueller’s investigation, we will have to wait and see how Attorney General Barr chooses to go about sharing the report, if he ends up sharing the information at all. The information could disturb the Trump presidency and possibly give Democrats grounds for introducing articles of impeachment. 

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com